Journal Mobile Options
Table of Contents
Vol. 55, No. 3-4, 2007
Issue release date: October 2007
Neuropsychobiology 2007;55:167–170

A Preliminary Study of Dopamine Transporter Binding in Bipolar and Unipolar Depressed Patients and Healthy Controls

Amsterdam J.D. · Newberg A.B.
aDepartment of Psychiatry, The Depression Research Unit, and bDepartment of Radiology, Division of Nuclear Medicine, University of Pennsylvania School of Medicine, Philadelphia, Pa., USA

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


Objective: We examined striatal dopamine transporter (DAT) binding in bipolar and unipolar depressed patients and compared these values to those obtained from healthy control subjects using the selective DAT radioligand [99mTc]TRODAT-1 and single photon emission computed tomography imaging. We hypothesized that DAT levels might be higher in bipolar versus unipolar patients. Methods: [99mTc]TRODAT-1 scans were acquired from 5 bipolar and 10 unipolar patients and from 46 healthy controls. Distribution volume ratio (DVR) of [99mTc]TRODAT-1 binding affinity was calculated for regions of interest in the striatum. Results: Bipolar patients had greater DVR values compared to controls in the right posterior putamen (p = 0.001) and in the left caudate region (p = 0.007). Bipolar patients had modestly lower DAT binding in all brain regions examined, and a significantly lower DVR in the right caudate region compared to unipolar patients (p = 0.05). Conclusion: These data suggest that striatal DAT density may be increased in bipolar and unipolar depressed patients compared to controls, and that bipolar and unipolar depressed patients may have a different pattern of striatal DAT binding.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Byrum CE, Ahearn EP, Krishnan KR: A neuroanatomic model for depression. Prog Neuropsychopharmacol 1999;23:175–193.
  2. Rogers MA, Bradshaw JL, Pantelis C, Phillips JG: Frontostriatal deficits in unipolar major depression. Brain Res Bull 1998;47:297–310.
  3. Giros B, Jaber M, Jones SR, Wightman RM, Caron MG: Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter. Nature 1996;379:606–612.
  4. Jaber M, Jones S, Giros B, Caron MG: The dopamine transporter: a crucial component regulating dopamine transmission. Mov Disord 1997;12:629–633.
  5. Mozley PD, Schneider JS, Acton PD, Plossl K, Stern MB, Siderowf A, Leopold NA, Li PY, Alavi A, Kung HF: Binding of [99mTc]TRODAT-1 to dopamine transporters in patients with Parkinson’s disease and in healthy volunteers. J Nucl Med 2000;41:584–589.
  6. Mozley LH, Gur RC, Mozley PD, Gur RE: Striatal dopamine transporters and cognitive functioning in healthy men and women. Am J Psychiatry 2001;158:1492–1499.
  7. Brunswick DJ, Amsterdam JD, Mozley PD, Newberg AB: Greater availability of brain dopamine transporters in major depression shown by [99mTc]TRODAT-1 SPECT imaging. Am J Psychiatry 2003;160:1836–1841.
  8. Yang YK, Yeh TL, Yoa WJ, Lee IH, Chen PS: Greater availability of dopamine transporter and no change in availability of D2/D3 receptor in major depression: a dual isotope SPECT study. Acad Conf Taiwanese Soc Psychiatry, Chung-Hua, Taiwan, November 2004.
  9. Drevets WC, Price JL, Simpson JRJ, Todd RD, Reich T, Vannier M, Raichle ME: Subgenual prefrontal cortex abnormalities in mood disorders. Nature 1997;386:824–827.
  10. Laasonen-Balk T, Kuikka J, Viinamaki H, Husso-Saastamoinen M, Lehtonen J, Tiihonen J: Striatal dopamine transporter density in major depression. Psychopharmacology (Berl) 1999;144:282–285.
  11. Meyer JH, Kruger S, Wilson AA, et al: Lower dopamine transporter binding potential in striatum during depression. Neuroreport 2001;12:4121–4125.
  12. Spitzer RL, Gibbon M, Williams JBW: Structured clinical interview for Axis I DSM-IV disorders – patient edition. Washington, American Psychiatric Press, 1994.
  13. Williams JBW: A structured interview guide for the Hamilton Depression Rating Scale. Arch Gen Psychiatry 1988;45:742–747.
  14. Malison RT, Price LH, Berman R, et al: Reduced brain serotonin transporter availability in major depression as measured by [123I]-2β-carbomethoxy-3β-(4-iodophenyl)tropane and single photon emission computed tomography. Biol Psychiatry 1998;44:1090–1098.
  15. Bowden C, Cheetham SC, Lowther S, Katona CLE, Crompton MR, Horton RW: Reduced dopamine turnover in the basal ganglia of depressed suicides. Brain Res 1997;769:135–140.
  16. Sachdev P, Aniss AM: Slowness of movement in melancholic depression. Biol Psychiatry 1994;35:253–262.
  17. Caligiuri MP, Ellwanger J: Motor and cognitive aspects of motor retardation in depression. J Affect Disord 2000;57:83–93.
  18. Cummings JL: Depression and Parkinson’s disease: a review. Am J Psychiatry 1992;149:443–454.
  19. McHugh PR: The neuropsychiatry of basal ganglia disorders: a triadic syndrome and its explanation. Neuropsychiatry Neuropsychol Behav Neurol 1989;2:239–247.
  20. Anand A, Verhoeff P, Seneca N, Zoghbi SS, Seibyl JP, Charney DS, Innis RB: Brain SPECT imaging of amphetamine-induced dopamine release in euthymic bipolar disorder patients. Am J Psychiatry 2000;157:1108–1114.
  21. Lammers CH, D’Souza U, Qin ZH, Lee SH, Yajima S, Mouradian MM: Regulation of striatal dopamine receptors by estrogen. Synapse 1999;34:222–227.
  22. Gardiner SA, Morrison MF, Mozley PD, Mozley LH, Brensinger C, Bilker W, Newberg AB, Battistini M: Pilot study on the effect of estrogen replacement therapy on brain dopamine transporter availability in healthy, postmenopausal women. Am J Geriatr Psychiatry 2004;12:621–630.
  23. Kugaya A, Seneca NM, Snyder PJ, et al: Changes in human in vivo serotonin and dopamine transporter availabilities during chronic antidepressant administration. Neuropsychopharmacology 2003;28:413–420.

Pay-per-View Options
Direct payment This item at the regular price: USD 33.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 23.00